ETF Quote Details
|NAV (month end)||37.92|
|Premium (+)/Discount (-) (month end)||-1.08|
Zacks Premium Research for PBE
|Zacks ETF Rank [?]||Strong Buy 1|
|ETF Risk [?]||Med|
|ETF Research Report|
Zacks proprietary quantitative models divide each set of ETFs following a similar investment strategy (style box/industry/asset class) into three risk categories- High, Medium, and Low. The aim of our models is to select the best ETFs within each risk category, so that investors can pick an ETF that matches their particular risk preference in order to better achieve their investment goals.
This is our ETF rating system that serves as a timeliness indicator for ETFs over the next 6 months:
Zacks Premium - The only way to get access to the Zacks Rank
ETF Expense Ratio
|Dividend (Yield)||$0.00 (0.00%)|
This is comprised of stocks of 30 U.S. biotechnology and genome companies. These are companies that are principally engaged in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes and companies that benefit significantly from scientific and technological advances in biotechnology and genetic engineering and research.
It is based on the Dynamic Biotechnology & Genome Intellidex Index. It invests at least 90% of its total assets in common stocks that comprise the Index which provides capital appreciation by thoroughly evaluating companies based on a variety of investment merit criteria, including fundamental growth, stock valuation, investment timeliness and risk factors.